Drug maker Gedeon Richter’s RGB-02 is undergoing development as a proposed biosimilar to the reference pegfilgrastim, Neulasta, and researchers recently reported on the results of a phase 3 clinical study of the drug versus its reference in patients with breast cancer who were receiving chemotherapy.
Drug maker Gedeon Richter’s RGB-02 is undergoing development as a proposed biosimilar to the reference pegfilgrastim, Neulasta, and researchers recently reported on the results of a phase 3 clinical study of the drug versus its reference in patients with breast cancer who were receiving chemotherapy.
The study, newly published in BMC Cancer, reports on a trial in 239 patients who were randomized to receive either the biosimilar (n = 121) or the reference (n = 118) pegfilgrastim as a once-per-chemotherapy-cycle fixed dose of 6 mg administered approximately 24 hours after chemotherapy was initiated. The study was conducted in a double-blind fashion for 2 cycles, after which patients in the reference arm were switched to the proposed biosimilar in an open-label extension for up to 6 cycles in total.
The study’s primary end point was the duration of severe neutropenia in cycle 1, defined as the number of consecutive days on which a patient had an absolute neutrophil count of less than 0.5 x 109/L. The predetermined limits were —1 day and 1 day; if the upper limit of the 95% CI for the difference in means was 1 day or less, and the lower bound of the CI for the difference in means was –1 day or more, then the means in the 2 arms were considered equivalent.
The mean duration of severe neutropenia in cycle 1 in the biosimilar arm was 1.7 days (±1.14 days), versus 1.6 days (±1.31 days) in the reference arm. The least squares means (95% CI) were 1.5 (range, 1.2-1.8) and 1.4 (range, 1.1-1.7) days, respectively. With the least squares mean difference of 0.1 days (95% CI, —0.2 to 0.4) falling within the prespecified equivalence margin, the investigators concluded that equivalence had been established.
In total, 87.2% of patients treated with the biosimilar experienced at least 1 adverse event (AE) during the study. During the 2-week double-blinded period, 80.2% of patients in the biosimilar arm reported AEs, versus 93.2% of patients in the reference arm. The most frequently reported AE was bone pain. Serious AEs were reported in 8.3% of patients in the biosimilar arm and 6.8% of patients in the reference arm, and the most commonly reported serious AE was febrile neutropenia.
The investigators report that an antidrug antibody (ADA) screening assay was negative in 96.1% of samples during the double-blind period, and that all samples that tested positive later tested negative in a confirmatory test. In the open-label period, again, all positive tests were negative upon confirmatory testing. No neutralizing ADA assays were performed.
The study’s authors concluded that therapeutic equivalence had been demonstrated between the biosimilar and the reference, that the 2 products had similar safety profiles, and that no immunogenicity was detected.
Results of the trial notwithstanding, the European Medicines Agency (EMA) recently announced that Gedeon Richter has withdrawn its marketing authorization for the drug, which it had hoped to sell under the brand name Efgratin.
According to the EMA, Gedeon Richter’s data package included results of 2 studies in healthy volunteers as well as the phase 3 study, and upon reviewing the data, the EMA “had some concerns and was of the provisional opinion that Efgratin could not have been approved for reducing neutropenia. The CHMP [Committee for Medicinal Products for Human Use] was concerned about the validity of results from studies on how the body handles Efgratin compared with Neulasta.” Additionally, the EMA indicated that the study lacked information on immunogenicity.
“Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not demonstrated that Efgratin was highly similar to Neulasta,” wrote the EMA in a February 1 notice of the marketing authorization application’s withdrawal.
Reference
Kahan Z, Grecea D, Smakal M, et al. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind, phase 3 clinical study vs reference pegfilgrastim in patients with breast cancer receiving chemotherapy. BMC Cancer. 2019;19(1): 122. doi: 10.1186/s12885-019-5329-6.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.